News on companion diagnostics and drug/test co-development.
AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.
Since 2017, the companies have been jointly developing an in vitro assay for measurement of sTREM-1 in plasma samples of septic shock patients.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
